Pre- to postdiagnosis leisure-time physical activity and prognosis in postmenopausal breast cancer survivors

Breast Cancer Research

Table 3 Time-dependent associations between leisure-time physical activity and overall mortality, breast cancer mortality, and recurrence-free survival in postmenopausal breast cancer survivors

Physical activity	Number	Events	Overall mortality, HR (95% CI)	Events	Breast cancer mortality, HR (95% CI)	Events	Recurrence-free survival, HR (95% CI)
Pre- and postdiagnosis physical activity^a,b	Predx/postdx	Predx/postdx		Predx/postdx		Predx/postdx
No activity	693/818	76/115	1.00 (ref.)	43/64	1.00 (ref.)	115/157	1.00 (ref.)
Low activity	692/504	73/46	0.94 (0.74–1.19)	43/24	0.94 (0.68–1.29)	115/92	1.18 (0.98–1.43)
Sufficient activity	657/720	58/46	0.73 (0.57–0.93)	29/27	0.64 (0.46–0.89)	99/80	0.82 (0.68–0.99)
Prediagnosis physical activity^c
No activity	677	73	1.00 (ref.)	41	1.00 (ref.)	112	1.00 (ref.)
Low activity	676	73	1.07 (0.77–1.49)	43	1.18 (0.76–1.83)	112	1.05 (0.80–1.38)
Sufficient activity	647	58	0.97 (0.68–1.38)	29	0.90 (0.55–1.46)	97	1.04 (0.79–1.37)
Postdiagnosis physical activity^d in insufficiently active women prediagnosis
No activity	662	91	1.00 (ref.)	53	1.00 (ref.)	121	1.00 (ref.)
Low activity	359	37	0.71 (0.48–1.06)	18	0.65 (0.37–1.16)	69	1.14 (0.84–1.55)
Sufficient activity	345	20	0.43 (0.26–0.72)	14	0.48 (0.25–0.91)	36	0.59 (0.40–0.86)
Postdiagnosis physical activity^d in sufficiently active women prediagnosis
No activity	91	23	1.00 (ref.)	10	1.00 (ref.)	34	1.00 (ref.)
Low activity	37	9	0.38 (0.16–0.88)	6	0.69 (0.18–2.56)	20	0.75 (0.41–1.38)
Sufficient activity	20	26	0.57 (0.30–1.08)	13	0.59 (0.22–1.64)	44	0.65 (0.39–1.09)

^aLeisure-time physical activity in MET-h/week was modelled as a time-dependent variable
^bAnalyses were adjusted for age at diagnosis, tumour size, nodal status, grade, ER/PR status, mode of detection, and menopausal hormone use at diagnosis, and were stratified by study centre and age at diagnosis in 5-year categories
^cAnalyses were adjusted for age at diagnosis, tumour size, nodal status, grade, ER/PR status, mode of detection, menopausal hormone use at diagnosis, chemotherapy, and hormone therapy, and were stratified by study centre and age at diagnosis in 5-year categories
^dAnalyses were adjusted for age at diagnosis, tumour size, nodal status, grade, ER/PR status, mode of detection, menopausal hormone use at diagnosis, and recurrences between diagnosis and follow-up, and were stratified by study centre and age at diagnosis in 5-year categories

ISSN: 1465-542X